Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. - Test2 - elhamkhani - TriplyDB

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

http://www.wikidata.org/entity/Q34202440

about

Tackling dengue fever: Current status and challenges The dengue vaccine pipeline: Implications for the future of dengue control Understanding the dengue viruses and progress towards their control Vaccine-mediated immunity against dengue and the potential for long-term protection against disease Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates Vaccines and immunization strategies for dengue prevention Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate Historical Perspectives on Flavivirus Research The 5' and 3' Untranslated Regions of the Flaviviral Genome.Dengue: challenges for policy makers and vaccine developers.A DNA microarray-based assay to detect dual infection with two dengue virus serotypes.Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeys Immune correlates for dengue vaccine development Utility, limitations, and future of non-human primates for dengue research and vaccine development Dengue vaccines: recent developments, ongoing challenges and current candidates.Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders.Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.Molecular determinants of plaque size as an indicator of dengue virus attenuation A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.Animal models of dengue virus infection Challenges in reducing dengue burden; diagnostics, control measures and vaccines.Developing a dengue vaccine: progress and future challenges.RNA-based viral vectors.A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.A recombinant live attenuated tetravalent vaccine for the prevention of dengue.Vaccines licensed and in clinical trials for the prevention of dengue.Development of Peptide Vaccines in Dengue.Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus.Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice.Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.Live attenuated vaccine: the first clinically approved dengue vaccine?Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties.Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.Entomopathogenic fungi and their potential for the management of Aedes aegypti (Diptera: Culicidae) in the Americas.

P2860

Q24288867-FDB1057E-E7A9-471E-8B57-3024D9302230 Q26314683-3AFA17D5-1B93-4DA5-97F3-47E42B39EA76 Q27011587-27D99C1C-1914-4593-A46E-59C21BEB4FB1 Q27014663-FB27744A-FEB8-4911-9F80-AB3727CE1874 Q27303669-021AD4A5-3F74-4884-A2DC-B78FF1216A4A Q28077521-3A6A22FC-F92F-4241-97D7-5412CD6B9401 Q29587283-4DDE5A78-0F40-4351-AB27-2AD9FC163B11 Q29994534-61910C3B-A4D3-4B31-AA7C-518865027DB9 Q32183359-5A222D4F-FB51-41EE-A1AC-04D7CB1815A2 Q33624327-380ECAC3-B0E2-4C7C-B4A1-492DFF08EB4F Q33775939-1D418D78-54E6-43B2-ADAE-DACB32C69A22 Q33800244-153F97FB-6C43-484D-AF9A-17549F3C79FD Q33924674-3F9695E2-F7BE-45C2-93EE-352A5966D8FB Q34238916-E19CE726-8CF6-4FE0-9C51-02DE41B28D43 Q34367194-B637986B-BA7F-44DC-8B17-BC52F3B41BA1 Q34630584-A6BE8F7D-678F-40B6-93A6-D9D032689E9E Q34759091-843E6C53-A5FC-40CF-BB50-F0625094C6C1 Q35548048-370EAEFD-E32E-4994-8563-4817488B69B4 Q35982791-74C194E3-601B-44B7-9BBF-82C8B55E64D9 Q36024479-681DC9DF-9609-4896-B9E4-06FBB58FA058 Q36208591-FE99F856-9114-4068-96A0-CBB593F76B82 Q36288109-CD1A07B8-9779-4002-9FB9-4043BBDF625F Q36667964-C43AAE57-2850-4E60-B0FD-57111A6303BE Q36906525-E54ED12B-B014-4596-BEA3-FCF662765D1C Q37336762-37A27949-8CC1-41B0-A9ED-ADCAABE12486 Q37987131-D01AF498-7D4C-447B-9423-B7E04C01C851 Q38140035-9B74ED88-D771-4223-A613-4D6177182EB1 Q38201151-E88C475E-360A-41C9-8BFF-F1C1A45F8C4A Q38266413-52E8D334-F51F-402F-B44E-E7DA6D0ADF5B Q38658737-E42064E3-BDE7-49AC-AD44-4C8445C591F4 Q38738484-953250EB-3794-46A4-9EF2-966BEF6AC266 Q39172722-82C82945-C2E9-4164-BE10-695A3D86C27B Q40038715-8C53055F-8731-4D67-A445-04545774EAB6 Q40042772-A13B615D-8AC4-47EB-92EB-71DCB643539F Q40190331-311C259D-02F2-476B-8B83-E1B8AA0717BC Q42985743-D6C95DD5-FF9E-4ACE-8C64-81B24F62B83D Q42998710-616CACD8-7DB5-4A3A-BB3C-583BBA6951DB Q47265866-99683B63-E230-416A-86F3-208CE5034922 Q47562022-2436C28D-F439-4812-A3EF-5A0DB8D0D6B6 Q48508987-B0C902CB-44CF-47C6-8C8C-11CD67126FE5

P2860

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

http://www.wikidata.org/entity/Q34202440

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Development of DENVax: a chime ...... otection against dengue fever.

@ast

Development of DENVax: a chime ...... otection against dengue fever.

@en

Development of DENVax: a chime ...... otection against dengue fever.

@nl

type

label

Development of DENVax: a chime ...... otection against dengue fever.

@ast

Development of DENVax: a chime ...... otection against dengue fever.

@en

Development of DENVax: a chime ...... otection against dengue fever.

@nl

prefLabel

Development of DENVax: a chime ...... otection against dengue fever.

@ast

Development of DENVax: a chime ...... otection against dengue fever.

@en

Development of DENVax: a chime ...... otection against dengue fever.

@nl

P1433

Q34202440-27AF8B02-E3C8-41CB-A93A-86B3BB98EEE8

P1476

Q34202440-24A1C6F0-447A-45E9-8777-B4E28E0A1001

P2093

Q34202440-02B1449D-DE77-4CD9-AEFA-C9F742E709AC

Q34202440-29DE5DBF-EBB4-4947-AD83-383F2EAC7F58

P2860

Q34202440-06BB1364-1F8A-49A0-820B-AF248806E57B

Q34202440-0B8633E4-B97A-4FBF-9186-F499A49A0CB3

Q34202440-121CBCEC-753F-439A-8673-AAB82C16EB14

Q34202440-14857F5E-B3EC-41F9-A8FC-E44CD69915C3

Q34202440-15AB867D-0B0C-4775-9FF8-80559816F3F5

Q34202440-15BC1D26-AFC3-4C24-A082-1D542F9189AC

Q34202440-2230DE59-F3A2-4D8E-8872-0848632E1FF1

Q34202440-2EC7E1BA-685C-4952-91B3-8C596FF9AC83

Q34202440-30FDB165-CAA4-4DA3-81F1-95C67BD9FCC8

Q34202440-331BFB4E-AA82-4BF1-BAC8-62AADFE4B0D4

P304

Q34202440-DEBAFC27-5FF9-4585-B7DF-46C8560B25BD

P31

Q34202440-CCDD1150-827A-43C6-A7DD-B3B1DE851A37

P356

Q34202440-112EB7BA-D741-45B5-B188-6C6F6A46D3EC

P407

Q34202440-D897AC6E-D76B-4398-8910-AA237915C348

P433

Q34202440-780A907A-8BB9-43E0-903D-9EA5629A487D

P478

Q34202440-C04D5887-B237-4D52-A84A-B19888148D04

P50

Q34202440-BE57E666-1965-479B-8B61-3BB4436627EA

Q34202440-C753DAC6-3E3D-434F-8A78-E3BE9CD07F44

P577

Q34202440-0BB78029-63F8-400D-AA40-12A020812BFA

P698

Q34202440-21953B42-9639-44D7-8F4A-AB656333B6BE

P921

Q34202440-EE81B792-3929-4CC3-8050-ADB57B7AE329

P932

Q34202440-5B34BEC3-1213-4110-A622-6C4882E95749

P356

J.VACCINE.2011.07.020

P1433

P1476

Development of DENVax: a chime ...... otection against dengue fever.

@en

P2093

Claire Y-H Huang

http://www.w3.org/2001/XMLSchema#string

Richard M Kinney

http://www.w3.org/2001/XMLSchema#string

P2860

Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host

New mouse model for dengue virus vaccine testing

Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes

Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus

Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity

P304

7251-7260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2011.07.020

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Jorge E. Osorio

Dan T Stinchcomb

P577

2011-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21777638

http://www.w3.org/2001/XMLSchema#string

P921

P932

4592106

http://www.w3.org/2001/XMLSchema#string